A study testing whether a new weekly shot from Boehringer Ingelheim, survodutide, can improve fatty liver disease.

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

• Male or female adults >=18 years of age at the time of screening, and at least the legal age of consent in countries where it is >18 years
• Body mass index (BMI) >=27 kg/m2(>=25 kg/m2 for Asian trial participants)
• Compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis.
• Magnetic resonance imaging proton density fat fraction (MRI-PDFF) fat fraction >=5% or FibroScan with controlled attenuation parameter (CAP) >=288 dB/m, obtained during the screening period or a historic MRI-PDFF <=12 weeks prior to randomisation (except for patients with 'cryptogenic cirrhosis' where MRI-PDFF <5% or FibroScan with CAP <288 dB/m is allowed). This inclusion criterion does not apply for participants with a recent (<=12 months prior to randomisation) liver biopsy showing steatosis/steatohepatitis.
• Further apply.

Key exclusion criteria

• Current or history (<5 years) of significant alcohol consumption, defined as an average of >140 g/week in female patients and >210 g/week in male patients, for a period of >3 consecutive months, or an inability to reliably quantify alcohol consumption based upon judgment of the investigator.
• Model of end-stage liver Disease (MELD) score >12 due to liver disease
• History or current (i.e. at screening) hepatic decompensation event of any of the following but not limited to:
• Portal hypertension-related upper gastrointestinal (GI) bleeding
• Ascites